# Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/β-catenin pathways

**Authors:** Yung-Ting Cheng, Kai-Hsi Lu, Shu-Ying Hong, Chung-Hsin Chen, Chao-Yuan Huang, Hsiu-Ni Kung

PMC · DOI: 10.1186/s12989-025-00656-3 · 2026-01-16

## TL;DR

This study shows how PM2.5, a type of air pollution, promotes bladder cancer progression by activating specific cell signaling pathways.

## Contribution

The study reveals a novel crosstalk mechanism between the MAPK/ERK and Wnt/β-catenin pathways in PM2.5-induced bladder cancer progression.

## Key findings

- PM2.5 exposure increases bladder cancer cell migration and invasion.
- MEK/ERK inhibition reduces PM2.5-induced β-catenin nuclear translocation and cancer progression.
- RNA sequencing identified the Wnt pathway as a key regulator in PM2.5-exposed bladder cancer cells.

## Abstract

Fine particulate matter 2.5 (PM2.5), a key indicator of air pollution, is classified as a human carcinogen. However, the link between air pollution and bladder cancer (BC) progression remains unclear. Dysregulation of the Wingless-related integration site (Wnt)/β-catenin and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways is a key driver of tumorigenesis in multiple cancers, including BC.

This study demonstrated that PM2.5 exposure enhances BC cell migration and invasion. Ribonucleic acid (RNA) sequencing identified the Wnt signaling pathway as a key regulator in PM2.5-exposed BC cells. Elevated protein levels of Wnt3A, Wnt5A, and β-catenin, along with the nuclear translocation of β-catenin, further highlighted the role of the PM2.5-activated Wnt/β-catenin pathway in promoting BC progression. The interaction between the Wnt/β-catenin and MAPK/ ERK pathways was examined using inhibitors and shRNAs. MEK or ERK inhibition not only suppressed PM2.5-induced upregulation of Wnt3A, Wnt5A, and β-catenin nuclear translocation but also significantly reduced the migration and invasion of PM2.5-exposed BC cells. Both pathways represent promising therapeutic targets, and several existing pathway-specific inhibitors may be repurposed for the future clinical management of PM2.5-induced BC progression.

PM2.5 promotes BC progression through both the MAPK/ERK and Wnt/β-catenin signaling pathways. MEK/ERK inhibition suppressed PM2.5-induced nuclear translocation of β-catenin, suggesting that the MAPK/ERK pathway functions upstream of the Wnt/β-catenin pathway. This study provides mechanistic insights into how PM2.5 exposure drives BC progression and offers a potential foundation for developing targeted therapies for PM2.5-associated BC.

The online version contains supplementary material available at 10.1186/s12989-025-00656-3.

## Linked entities

- **Genes:** WNT3A (Wnt family member 3A) [NCBI Gene 89780], WNT5A (Wnt family member 5A) [NCBI Gene 7474], ctnnb1.S (catenin beta 1 S homeolog) [NCBI Gene 380441]
- **Diseases:** bladder cancer (MONDO:0004986)

## Full-text entities

- **Genes:** APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CSNK1D (casein kinase 1 delta) [NCBI Gene 1453] {aka ASPS, CKI-delta, CKId, CKIdelta, FASPS2, HCKID}, WNT3A (Wnt family member 3A) [NCBI Gene 89780], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5894] {aka CMD1NN, CRAF, NS5, Raf-1, c-Raf}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, FZD5 (frizzled class receptor 5) [NCBI Gene 7855] {aka C2orf31, HFZ5, MCOPCB11}, Ptpra (protein tyrosine phosphatase, receptor type, A) [NCBI Gene 25167] {aka LRP}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, DVL1 (dishevelled segment polarity protein 1) [NCBI Gene 1855] {aka DRS2, DVL, DVL1L1}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, WIF1 (Wnt inhibitory factor 1) [NCBI Gene 11197] {aka WIF-1}, AXIN1 (axin 1) [NCBI Gene 8312] {aka AXIN, CMDOH, PPP1R49}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, Wnt2 (Wnt family member 2) [NCBI Gene 114487] {aka Wnt}, Wnt5a (Wnt family member 5A) [NCBI Gene 64566], PRCP (prolylcarboxypeptidase) [NCBI Gene 5547] {aka HUMPCP, PCP}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, PORCN (porcupine O-acyltransferase) [NCBI Gene 64840] {aka DHOF, FODH, MG61, PORC, PPN}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}
- **Diseases:** SRM (MESH:D053591), urothelial cell carcinomas (MESH:D002280), lung (MESH:D008171), bladder carcinogenesis (MESH:D063646), bladder transitional cell carcinoma (MESH:D002295), APS (MESH:D016884), CRC (MESH:D015179), death (MESH:D003643), metastasis (MESH:D009362), toxicity (MESH:D064420), BC (MESH:D001749), urothelial carcinoma (MESH:D014523), ovarian and nasopharyngeal cancers (MESH:D010051), Cancer (MESH:D009369), melanoma (MESH:D008545), lung epithelial (MESH:D009375), SABC (MESH:C531633), lung alveolar cancer (MESH:D008175), Fibrosarcoma (MESH:D005354), infection (MESH:D007239), RAS (MESH:D012509), carcinogenic (MESH:D011230)
- **Chemicals:** LY3214996 (MESH:C000719760), binimetinib (MESH:C581313), PKF118-310 (MESH:C548732), trypan blue (MESH:D014343), dA (MESH:C025953), PKF115-584 (MESH:C538949), saline (MESH:D012965), acrolein (MESH:D000171), water (MESH:D014867), CO2 (MESH:D002245), PBS (MESH:D007854), PM (MESH:D011399), 2-mercaptoethanol (MESH:D008623), 3,3',5,5'-tetramethylbenzidine (MESH:C021758), crystal violet (MESH:D005840), MK-8353 (MESH:C000632607), glycerol (MESH:D005990), regorafenib (MESH:C559147), Ammonium persulfate (MESH:C031276), Penicillin (MESH:D010406), CGP049090 (MESH:C538948), Tween 20 (MESH:D011136), paraformaldehyde (MESH:C003043), trametinib (MESH:C560077), Triton X-100 (MESH:D017830), SCH772984 (MESH:C587178), EDTA (MESH:D004492), Streptomycin (MESH:D013307), ethanol (MESH:D000431), sulfate (MESH:D013431), puromycin (MESH:D011691), biotin (MESH:D001710), TEMED (MESH:C005798), isopropanol (MESH:D019840), phalloidin (MESH:D010590), APS (MESH:D000250), Hoechst (-), acrylamide (MESH:D020106), BVD-523 (MESH:C000618314), Sodium (MESH:D012964), HCl (MESH:D006851), PAH (MESH:D011084), ICG-001 (MESH:C492448), 4',6-diamidino-2-phenylindole (MESH:C007293), U0126 (MESH:C113580), cobimetinib (MESH:C574276), selumetinib (MESH:C517975), bromophenol blue (MESH:D001978), Trizol (MESH:C411644), Methyl 3-[(4-methylphenyl)sulfonyl]amino-benzoate (MESH:C000624705), Alexa Fluor  488 (MESH:C000711379), Arg-Gly-Asp (MESH:C047981), GDC-0994 (MESH:C000619637), 1-Bromo-3-chloro-propane (MESH:C560814), SDS (MESH:D012967), DEPC (MESH:D004047)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Nicotiana tabacum (American tobacco, species) [taxon 4097], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** BRAFV600E, K004M
- **Cell lines:** TSGH 8301 — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_A342), BOX-5 — Mus musculus (Mouse), Transformed cell line (CVCL_5U93), T24 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0554), U0126 — Homo sapiens (Human), Transformed cell line (CVCL_K395), TSGH — Homo sapiens (Human), Gastric signet ring cell adenocarcinoma, Cancer cell line (CVCL_5379)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12828959/full.md

---
Source: https://tomesphere.com/paper/PMC12828959